Devote data can give Novo more negotiation power
Detailed data from Novo Nordisk’s comparative Devote study confirms that the company’s new insulin is as safe as and markedly more effective than its rival, the top-selling Lantus from Sanofi. This information can strengthen Novo’s position in the important ongoing negotiations with US payers.
BY MARTIN HAVTORN PETERSEN
At the end of November last year, the Danish diabetes giant Novo Nordisk announced topline data from its Devote trial. The data showed that the company's promising basal insulin Tresiba surpassed the world’s best selling insulin drug, Lantus from Novo’s arch rival Sanofi.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Novo EVP: Tresiba will be in a league of its own
For abonnenter
Novo’s US head is ready for turnaround
For abonnenter
Novo wins market shares in US basal insulin segment
For abonnenter
